Fast Market Research announces the availability of the new TechNavio report,"Global Next-Generation Biologics Market 2016-2020", on their comprehensive research portal

Boston, MA -- (SBWire) -- 01/11/2017 --According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a"virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings." Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.

Get More Details on this Report and a Full Table of Contents at Global Next-Generation Biologics Market 2016-2020

Technavio's analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-F. Hofmann-La Roche
-Novo Nordisk
-Sanofi
-Takeda Pharmaceuticals

Other prominent vendors

-Aastrom Biosciences
-AbbVie
-AbGenomics
-Acologix
-ADC Therapeutics
-Adocia
-Agensys
-AlloCure
-AlloSource
-ALMAC Group
-Alphatec Spine
-Ambrx
-Amorcyte
-Argos Therapeutics
-Astellas Pharma
-AstraZeneca
-Athersys
-Avita Medical
-Baxter
-Bayer HealthCare
-Bellicum Pharmaceuticals
-BioCardia
-Biocon
-Biodel
-BIOGENOMICS
-BioLife Solutions
-BioRestorative Therapies
-BioTissue Technologies
-Bluebird Bio
-Boehringer Ingelheim
-BrainStorm Cell Therapeutics
-Calimmune
-Capricor
-CARBOGEN AMCIS
-Cell Medica
-Celldex Therapeutics
-Celyad (Cardio3 BioSciences)
-Cesca
-CryoLife
-CSL Behring
-Cynata Therapeutics
-Daiichi Sankyo
-Dance Biopharm
-Dendreon
-Diasome Pharmaceuticals
-DiscGenics
-Endo Pharmaceuticals
-Esperance Pharmaceuticals
-Exsulin
-Fate Therapeutics
-Fibrocell Science
-Formation Biologics
-Forticell Bioscience
-Fortress Biotech
-Gamida Cell
-GENEREX
-Genmab
-Geron
-GlaxoSmithKline
-Harvard Apparatus Regenerative Technology
-Healthpoint
-Histogen
-Histogenics
-Humacyte
-Immunocellular Therapeutics
-Immunogen
-Integra LifeSciences
-InVivo Therapeutics
-ISTO Technologies
-Juno Therapeutics
-Juventas Therapeutics
-Kairos Therapeutics
-Kensey Nash
-Kiadis Pharma
-Kinetic Concept
-Living Cell Technologies
-MacroGenics
-MannKind
-MaxCyte
-MedImmune
-Medtronic
-Mersana Therapeutics
-Mesoblast
-MiMedx
-Nanofiber Solutions
-Nanotope
-Neuralstem
-NewLink Genetics
-NGM Biopharmaceuticals
-Northwest Biotherapeutics
-Novartis
-NovaRx
-Ocata Therapeutics
-Opexa Therapeutics
-Oramed Pharmaceuticals
-Organovo
-Orteq
-Orthofix
-Osiris Therapeutics
-Osteotech
-OXFORD BioTherapeutics
-Pfizer
-PhaseBio Pharmaceuticals
-Pluristem Therapeutics
-Prima BioMed
-Q Therapeutics
-ReproCELL
-RhinoCyte
-RTI Surgical
-SanBio
-Sangamo
-Shire Regenerative Medicine
-STEMCELL Technologies
-Stemcentrx
-Stratatech
-Synthon Biopharmaceuticals

Companies Mentioned in this Report: Biogen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Aastrom Biosciences, AbbVie, AbGenomics, Acologix, ADC Therapeutics, Adocia, Agensys, AlloCure, AlloSource, ALMAC Group, Alphatec Spine, Ambrx, Amorcyte, Argos Therapeutics, Astellas Pharma, AstraZeneca, Athersys, Avita Medical, Baxter, Bayer HealthCare, Bellicum Pharmaceuticals, BioCardia, Biocon, Biodel, BIOGENOMICS, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Calimmune, Capricor, CARBOGEN AMCIS, Cell Medica, Celldex Therapeutics, Celyad, Cesca, CryoLife, CSL Behring, Cynata Therapeutics, Daiichi Sankyo, Dance Biopharm, Dendreon, Diasome Pharmaceuticals, DiscGenics, Endo Pharmaceuticals, Esperance Pharmaceuticals, Exsulin, Fate Therapeutics, Fibrocell Science, Formation Biologics, Forticell Bioscience, Fortress Biotech, Gamida Cell, GENEREX, Genmab, Geron, GlaxoSmithKline, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics, Immunogen, Integra LifeSciences, InVivo Therapeutics, ISTO Technologies, Juno Therapeutics, Juventas Therapeutics, Kairos Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MacroGenics, MannKind, MaxCyte, MedImmune, Medtronic, Mersana Therapeutics, Mesoblast, MiMedx, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, NGM Biopharmaceuticals, Northwest Biotherapeutics, Novartis, NovaRx, Ocata Therapeutics, Opexa Therapeutics, Oramed Pharmaceuticals, Organovo, Orteq, Orthofix, Osiris Therapeutics, Osteotech, OXFORD BioTherapeutics, Pfizer, PhaseBio Pharmaceuticals, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, ReproCELL, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, STEMCELL Technologies, Stemcentrx, Stratatech, Synthon Biopharmaceuticals, TEI Biosciences, Tengion, Thermalin Diabetes, TiGenix, Tissue Genesis, TissueGene, Tolerion, VentriNova, Vericel, VeroScience, ViaCyte, VistaGen Therapeutics, vTv Therapeutics, Wockhardt, XOMA, Zimmer-Biomet, Zymeworks

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156.

Browse all Biotechnology research reports at Fast Market Research

You may also be interested in these related reports:

-Global Spine Biologics Market 2016-2020
-Global Wound Biologics Market 2016-2020
-Human Insulin Market - Forecasts to 2020
-Global Biosimilars Market 2016-2020
-Global mAb Biosimilars Market 2016-2020